Metastatic Colorectal Cancer: A Systematic Review of the Value of Current Therapies

被引：70

作者：

Goldstein, Daniel A. ^{[1
]}

Zeichner, Simon B. ^{[1
]}

Bartnik, Catherine M. ^{[2
]}

Neustadter, Eli ^{[1
]}

Flowers, Christopher R. ^{[1
]}

机构：

[1] Emory Univ, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA

[2] Emory Univ, Dept Med, Atlanta, GA 30322 USA

来源：

CLINICAL COLORECTAL CANCER | 2016年 / 15卷 / 01期

关键词：

Chemotherapy; Colorectal cancer; Cost-effectiveness; Incremental cost effectiveness ratio; Value; FLUOROURACIL DOSE ADJUSTMENT; COST-EFFECTIVENESS; UNITED-STATES; GLUCURONOSYLTRANSFERASE; 1A1; 2-STAGE HEPATECTOMY; BOLUS FLUOROURACIL; RANDOMIZED-TRIAL; 1ST-LINE THERAPY; IRINOTECAN; MULTICENTER;

D O I：

10.1016/j.clcc.2015.10.002

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

To evaluate, from a US payer perspective, the cost-effectiveness of treatment strategies for metastatic colorectal cancer (mCRC), we performed a systematic review of published cost-effectiveness analyses. We identified 14 papers that fulfilled our search criteria and revealed varying levels of value among current treatment strategies. Older agents such as 5-fluorouracil, irinotecan, and oxaliplatin provide high-value treatments. More modern agents targeting the EGFR or VEGF pathways, such as bevacizumab, cetuximab, and panitumumab, do not appear to be cost-effective treatments at their current costs. The analytical methods used within the papers varied widely, and this variation likely plays a significant role in the heterogeneity in incremental cost-effectiveness ratios. The cost-effectiveness of current treatment strategies for mCRC is highly variable. Drugs recently approved by the US Food and Drug Administration for mCRC are not cost-effective, and this is primarily driven by high drug costs.

引用

页码：1 / 6

页数：6

共 37 条

[1] Cost-effectiveness of simultaneous resection and RFA versus 2-stage hepatectomy for bilobar colorectal liver metastases [J].

Abbott, Daniel E. ;

Sohn, Vance Y. ;

Hanseman, Dennis ;

Curley, Steven A. .

JOURNAL OF SURGICAL ONCOLOGY, 2014, 109 (06) :516-520

[2]

[Anonymous], ISRN MINIM INVASIVE

[3] Cost-Effectiveness Analysis of Screening for KRAS and BRAF Mutations in Metastatic Colorectal Cancer [J].

Behl, Ajay S. ;

Goddard, Katrina A. B. ;

Flottemesch, Thomas J. ;

Veenstra, David ;

Meenan, Richard T. ;

Lin, Jennifer S. ;

Maciosek, Michael V. .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2012, 104 (23) :1785-1795

[4] Radiofrequency ablation of hepatic malignancies: Inexpensive and minimally invasive but should it replace resection? [J].

Bilchik, AJ ;

Faries, M .

ANNALS OF SURGICAL ONCOLOGY, 2003, 10 (09) :1002-1004

[5] Individual Fluorouracil Dose Adjustment in FOLFOX Based on Pharmacokinetic Follow-Up Compared With Conventional Body-Area-Surface Dosing: A Phase II, Proof-of-Concept Study [J].

Capitain, Olivier ;

Asevoaia, Andreaa ;

Boisdron-Celle, Michele ;

Poirier, Anne-Lise ;

Morel, Alain ;

Gamelin, Erick .

CLINICAL COLORECTAL CANCER, 2012, 11 (04) :263-267

[6] Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: A Multicenter study of the Gruppo Oncologico Dell'Italia Meridionale [J].

Colucci, G ;

Gebbia, V ;

Paoletti, G ;

Giuliani, F ;

Caruso, M ;

Gebbia, N ;

Carteni, G ;

Agostara, B ;

Pezzella, G ;

Manzione, L ;

Borsellino, N ;

Misino, A ;

Romito, S ;

Durini, E ;

Cordio, S ;

Di Seri, M ;

Lopez, M ;

Maiello, E .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (22) :4866-4875

[7] The cost-effectiveness of total joint arthroplasty: A systematic review of published literature [J].

Daigle, Meghan E. ;

Weinstein, Alexander M. ;

Katz, Jeffrey N. ;

Losina, Elena .

BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, 2012, 26 (05) :649-658

[8] Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis [J].

De Roock, Wendy ;

Claes, Bart ;

Bernasconi, David ;

De Schutter, Jef ;

Biesmans, Bart ;

Fountzilas, George ;

Kalogeras, Konstantine T. ;

Kotoula, Vassiliki ;

Papamichael, Demetris ;

Laurent-Puig, Pierre ;

Penault-Llorca, Frederique ;

Rougier, Philippe ;

Vincenzi, Bruno ;

Santini, Daniele ;

Tonini, Giuseppe ;

Cappuzzo, Federico ;

Frattini, Milo ;

Molinari, Francesca ;

Saletti, Piercarlo ;

De Dosso, Sara ;

Martini, Miriam ;

Bardelli, Alberto ;

Siena, Salvatore ;

Sartore-Bianchi, Andrea ;

Tabernero, Josep ;

Macarulla, Teresa ;

Di Fiore, Frederic ;

Gangloff, Alice Oden ;

Ciardiello, Fortunato ;

Pfeiffer, Per ;

Qvortrup, Camilla ;

Hansen, Tine Plato ;

Van Cutsem, Eric ;

Piessevaux, Hubert ;

Lambrechts, Diether ;

Delorenzi, Mauro ;

Tejpar, Sabine .

LANCET ONCOLOGY, 2010, 11 (08) :753-762

[9] American Society of Clinical Oncology Perspective: Raising the Bar for Clinical Trials by Defining Clinically Meaningful Outcomes [J].

Ellis, Lee M. ;

Bernstein, David S. ;

Voest, Emile E. ;

Berlin, Jordan D. ;

Sargent, Daniel ;

Cortazar, Patricia ;

Garrett-Mayer, Elizabeth ;

Herbst, Roy S. ;

Lilenbaum, Rogerio C. ;

Sima, Camelia ;

Venook, Alan P. ;

Gonen, Mithat ;

Schilsky, Richard L. ;

Meropol, Neal J. ;

Schnipper, Lowell E. .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (12) :1277-+

[10] Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: Results of a multicenter randomized trial of patients with metastatic colorectal cancer [J].

Gamelin, Erick ;

Delva, Remy ;

Jacob, Jacques ;

Merrouche, Yacine ;

Raoul, Jean Luc ;

Pezet, Denis ;

Dorval, Etienne ;

Piot, Gilles ;

Morel, Alain ;

Boisdron-Celle, Michele .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (13) :2099-2105

← 1 2 3 4 →